Access

News and Views


Nature Medicine 8, 1352 - 1353 (2002)
doi:10.1038/nm1202-1352

Vessel maneuvers: Vaccine targets tumor vasculature

Michael S. O'Reilly1

  1. Departments of Radiation Oncology and Cancer Biology University of Texas M.D. Anderson Cancer Center Houston, Texas, USA e-mail: moreilly@mdanderson.org


A new oral vaccine targets a receptor in newly forming blood cells and thwarts angiogenesis in mouse models of cancer (pages 1369–1375).


Since its inception over three decades ago, the field of angiogenesis has made significant progress and has led to an improved understanding of physiological and pathophysiological conditions1. However, a number of obstacles remain before the anti-tumor effects of anti-angiogenic therapy in mice2 can be translated to clinical practice.

MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated

REVIEWS
Clinical translation of angiogenesis inhibitors
Nature Reviews Cancer Review Article (01 Oct 2002)

$rb.Type.Code